IP Library Granted Patent US 11,697,848
Granted Patent B2
US 11,697,848 · App. 16/967,659 · Granted Jul 11, 2023

Reagent and method for fluorescence quantitative real-time PCR detection of RCL

Inventors: Fang Liu (Shanghai, CN); Liping Lan (Shanghai, CN); Yutian Wei (Shanghai, CN); Xun Ye (Shanghai, CN); Li Zhang (Shanghai, CN); Jiaqi Huang (Shanghai, CN); Yihong Yao (Shanghai, CN)
Assignee: Cellular Biomedicine Group, Inc.
C12Q1/6876C12Q1/686C12Q1/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,697,848
App. No.
16/967,659
Granted
Jul 11, 2023
Kind
B2
Abstract

The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.

Claims (13)

1. A reagent combination comprising:

(i) a first primer pair for specific amplification of vesicular stomatitis virus G protein (VSV-G) gene and a first probe,

wherein, the first primer pair comprises: a first forward primer consisting of the sequence of SEQ ID NO: 1, and a first reverse primer consisting of the sequence of SEQ ID NO:2;

wherein the first probe consists of the sequence of SEQ ID NO: 3 and a first detectable label; and

(ii) a second primer pair for specific amplification of VSV-G gene and a second probe,

wherein, the second primer pair comprises: a second forward primer consisting of the sequence of SEQ ID NO: 4, and a second reverse primer consisting of the sequence of SEQ ID NO: 5;

wherein the second probe consists of the sequence of SEQ ID No: 6 and a second detectable label.

2. The reagent combination of claim 1 , wherein the amplification efficiency of the reagent combination for detecting replication competent lentivirus (RCL) is ≥90%.

3. A detection kit comprising the reagent combination of claim 1 .

4. The detection kit of claim 3 , wherein the kit further comprises reagents for amplification.

5. The reagent combination of claim 2 , wherein the amplification efficiency of the reagent combination for detecting RCL is ≥92%.

6. The reagent combination of claim 5 , wherein the amplification efficiency of the reagent combination for detecting RCL is ≥95%.

7. The reagent combination of claim 1 , wherein the first and the second detectable labels are fluorophores.

Assignments (5)
CHANGE OF NAME Recorded Jan 17, 2024
From: CELLULAR BIOMEDICINE GROUP, INC.
To: ABELZETA INC.
Reel/Frame 066340/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2022
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: CELLULAR BIOMEDICINE GROUP INC.
Reel/Frame 062152/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2021
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 057481/0551 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2021
From: WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 057481/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2021
From: LIU, FANG; LAN, LIPING; WEI, YUTIAN; YE, XUN; ZHANG, LI; HUANG, JIAQI; YAO, YIHONG
To: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Reel/Frame 057342/0098 →
Priority Claims (1)
CN 201810114113.2 · Feb 5, 2018 · national
Continuity (1)
Related Publication 20210214789A1 · Jul 15, 2021